Slow day at work today and as if you all don't alr

Slow day at work today and as if you all don't already know this but regarding upcoming "milestones":

1. Phase II Oncology Trial in Colorectal Cancer:

* FDA Clearance: In November 2024, the FDA approved CytoDyn's Phase II trial to assess leronlimab's efficacy in patients with relapsed or refractory microsatellite-stable colorectal cancer.

*Trial Initiation: A kickoff meeting occurred in late November 2024, with patient enrollment slated to begin in early 2025.


2. Preclinical Studies in Metabolic-Associated Steatohepatitis (MASH):

**Ongoing Research: As of June 2024, CytoDyn initiated preclinical studies to evaluate leronlimab's potential in reversing liver fibrosis associated with MASH.

**Upcoming Results: Findings from these studies are anticipated in January 2025.


3. Pilot Study in Alzheimer's Disease:

***Protocol Finalization: CytoDyn has completed the protocol for a pilot study to assess leronlimab in patients with mild to moderate Alzheimer's disease.

***Regulatory Submissions: The protocol will soon be submitted to both the FDA and the Institutional Review Board (IRB) at Cornell Medical Center in New York.

4. Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS):

****NIH Application: In September 2024, CytoDyn applied to the NIH's RECOVER-TLC group to include leronlimab in upcoming Long COVID treatment studies.

****Pending Decision: A decision from the NIH is expected in the coming months.

5. HIV Program:

*****Clinical Hold Status: As of February 2024, CytoDyn submitted a revised HIV clinical trial protocol to the FDA, aiming to address the clinical hold on its HIV program.

*****Awaiting FDA Response: The company is awaiting feedback from the FDA regarding the potential lifting of the clinical hold.

LETS GO!!!